By Rachel Leven
Sept. 29 — Companies are filling gaps in international and federal environmental rules by studying unregulated areas and implementing their own affirmative compliance standards, John Cruden, the nominee to head the Justice Department's Environment and Natural Resources Division, said Sept. 29.
This phenomenon, known as “private governance,” can be seen in issues such as regulating pharmaceutical residue in the environment, which the Environmental Protection Agency doesn't yet regulate. Additionally, some nongovernmental entities offer “certification standards” for compliance on issues such as food security and obtaining timber in an environmentally sensitive manner, Cruden said.
By conducting its own private governance, a company could bolster its brand, improve environmental impacts across its supply chain and give itself an economic edge over its competitors, Cruden said. Moreover, companies' own compliance standards that are set to proactively protect the environment could be considered as best practices if the government moves to create regulations, Cruden said.
“Fundamentally, this is a concept of enforcement … being governed by nongovernment entities, primarily by [nongovernmental organizations] and corporations,” said Cruden, who is yet to be confirmed to the DOJ position and is the president of the Environmental Law Institute. Cruden made the comments at the Environmental Compliance and Commitment Legal Summit.
Cruden highlighted work by AstraZeneca to address pharmaceutical residue in the environment as an example of private governance. The pharmaceutical company proactively researches the potential risks and effects of exposure for the environment and the public, Cruden said.
AstraZeneca used its research to determine Environmental Reference Concentrations, or average concentrations of certain pharmaceutical ingredients in its surface water discharges that would be unlikely to harm the environment.
The company also identified Maximum Tolerable Concentrations, or “short term peak emissions associated with batch-wise production and cleaning activities,” for certain pharmaceutical ingredients, AstraZeneca said on its website.
The company aims to comply with safe concentration levels at manufacturing facilities inside and outside of the U.S., it said.
To contact the reporter on this story: Rachel Leven in New York at firstname.lastname@example.org
To contact the editor responsible for this story: Larry Pearl at email@example.com
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)